Essilor will present the two–year clinical trial results of its Stellest lens at the ‘World Society of Paediatric Ophthalmology and Strabismus (WSPOS) Connect 2 the World’ virtual congress 2021 on 25 September. The session will provide an international platform to interact with leading paediatric ophthalmologists, researchers, eye care practitioners and myopia experts on myopia management.
For the second year in a row, Essilor will participate at the conference, as part of its mission to engage, share insights and provide innovative solutions to address the growing problem of myopia together. The randomized three–year clinical trial started in July 2018 in the WEIRC (Wenzhou Medical University – Essilor International Research Center) in China on 167 myopic schoolchildren aged 8–13 years, who received three types of spectacle lenses – lenses with highly aspherical lenslets (HAL), lenses with slightly aspherical lenslets (SAL), and single–vision lenses.
The clinical trial showed that higher lenslet asphericity led to higher myopia control efficacy, so HAL lenses were more effective at slowing down myopia progression than SAL lenses, when compared to single–vision lenses. Essilor Stellest lenses have the same optical design as the HAL lenses. The study also demonstrated that the wearing time significantly influenced the treatment outcome. After two years, children wearing Essilor Stellest lenses saved 0.99 diopters of myopia degree on average (67% slow–down in myopia progression on average), compared to single vision lenses, when worn 12 hours or more per day, every day.
During the satellite session, a review of the different generations of myopia control spectacle lenses, the design of the Essilor Stellest lens and the two–year clinical trial results will be presented by Dr. Damien Paillé, Dr. Guillaume Giraudet and Dr. Björn Drobe respectively, from Essilor International’s research and development team. The session will be introduced by Dr. Ken Nischal, WSPOS Co–founder, and Olga Prenat, Vice President, Global Education and Professional Relations, Essilor International.
Norbert Gorny, Co–Chief Operating Officer, Essilor International, commented on the results, “It has been well–established that early intervention is critical to preventing high myopia from developing. Given the increased risk of high myopia with myopia onset at a younger age, the Essilor Stellest™ lens can help in effectively slowing down myopia progression even during early childhood, reducing myopia–related risks later in life. So we truly hope that it is the catalyst for increased myopia management in practices globally. With this lens, we continue to lead the way in developing a safe, convenient and effective way to manage the increasing myopia problem.”